From: Lectins and lectibodies: potential promising antiviral agents
Lectin | Cytotoxicity | Mitogenicity | Activity (nM unless otherwise noted) | Refs. |
---|---|---|---|---|
AH | No | No | HIV-1 (2–110), HIV-2 (3–14), | |
CV-N | Yes | Yes | HIV (0.1–33.7), HCV (1.6), Ebo (100) | |
MVN | No | No | HIV-1 (2–167), HCV (31–39) | |
MVL | Yes | Unk | HIV-1 (30–37), HCV (14–34) | |
SVN | No | Unk | HIV-1 (0.3–22), EBOV (41) | |
OAA | Yes | Unk | HIV-1 (30–45) | |
PRM-A | No | No | HIV-1/2 (1.6-10 µM), SIV (5 µM) | |
GRFT | No | No | HIV (0.03–1.3), HCV (6.7–13.9), SARS-Cov (48), JEV (20), HSV-2(230), HPV (0.4–1.39 µM), NiV (20–60), ANDV (180–230) | [104,105,106,107,108,109, 113,114,115,116,117,118,119,120,121,122,123,124, 178, 195, 196] |
BCA | No | Unk | HIV-1 (8.2), influenza H3N2 (18.8–74.2) | [64] |
BanLec | Yes | Yes | HIV-1 (0.8–14), HIV-2 (3.7) | |
GNA | No | Unk | HCV (11.1–25.5), influenza A H1N1 (0.1–268), influenza A H3N2 (0.4–6.4), influenza B (0.016–0.89), HIV-1 (0.3–4.7 μg/ml), HIV-2 (0.1–0.2 μg/ml), SIV (2.7 μg/ml), FIV (0.09 μg/ml), SARS-COV (6.2 μg/ml), FIPV (3.9 μg/ml) | |
HHA | No | Unk | Influenza A H1N1 (0.05–121), influenza A H3N2 (0.10–3), influenza B (0.015–1.8), HIV-1 (0.3–3.2 μg/ml), HIV-2 (0.1–0.2 μg/ml), SIV (0.6 μg/ml), FIV (0.1 μg/ml), SARS-COV (3.2 μg/ml), FIPV (2.6 μg/ml) | |
PCL | No | Unk | HIV-1 (0.05–0.08 μg/ml), HIV-2 (0.08–0.1 μg/ml) | |
UDA | Yes | Yes | HIV-1(100–180), HIV-2 (240–420), HSV-1(9.6- > 11 µM), HSV-2 (1.1–1.3 µM), SIV (130–190), MSV (> 20 µg/ml), SARS-CoV (0.9–2.6 µg/ml), influenza A H1N1 (5–435), influenza A H3N2 (5.8–83), and influenza B (0.64–14) | |
NICTABA | No | Unk | HSV-1 (171–263), HSV-2 (41–64), influenza A H1N1 (21–43), influenza A H3N2 (13–23), influenza B (11), RSV (105), and DENV type 2 (323–729) | |
PHA | No | Yes | SARS-CoV-2 (141–217.9), HIV-1 (50 µg/ml) | |
LCA | No | Unk | SARS-CoV-2 (152.3–186.6) | [116] |
SVL | No | Unk | HIV-1 (2.8 µM) | [14] |
CGL | No | Yes | HIV-1 (2.5 µM) | [14] |